Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $20.4 million.

  • Centessa Pharmaceuticals' Accumulated Expenses rose 7.78% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 7.78%. This contributed to the annual value of $50.9 million for FY2024, which is 84.46% up from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Accumulated Expenses stood at $20.4 million, which was down 14.84% from $24.0 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Accumulated Expenses high stood at $50.9 million for Q4 2024, and its period low was $15.3 million during Q1 2023.
  • In the last 3 years, Centessa Pharmaceuticals' Accumulated Expenses had a median value of $21.4 million in 2024 and averaged $24.0 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first dropped by 25.30% in 2023, then surged by 84.46% in 2024.
  • Centessa Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $24.5 million in 2022, then climbed by 12.52% to $27.6 million in 2023, then spiked by 84.46% to $50.9 million in 2024, then increased by 7.78% to $20.4 million in 2025.
  • Its Accumulated Expenses stands at $20.4 million for Q3 2025, versus $24.0 million for Q2 2025 and $19.1 million for Q1 2025.